CD4 and neoplasm: Strengthening this idea, we have described an immunomodulating effect of the GS-PTX-HA treatment, modifying subpopulations of immune cells including CD4+ T lymphocytes and NK cells in the tumor-draining lymph nodes and in the spleen, respectively.